Merck Millipore has introduced Parteck SRP 80, a functional excipient for oral sustained-release formulations
Merck Millipore's Parteck SRP 80 functional excipient for oral sustained-release formulations
Parteck SRP 80 is a polyvinyl alcohol (PVA) based excipient designed for modified-release applications for pharmacokinetics, pharmacodynamics and the bioavailability of actives.
The new excipient is fully synthetic and suitable for direct compression processes.
Parteck SRP 80 is compliant with European Pharmacopoeia, United States Pharmacopoeia and Japanese Pharmacopoeia Excipients and will be part of Merck Millipore's Emprove programme to facilitate regulatory filing and registration processes.
Andrew Bulpin, executive vice president of process solutions, Merck Millipore, said: "Pharmaceutical excipients play an essential role in the development of safe and effective medicines.
"Parteck SRP 80 represents a new choice for customers looking to formulate prolonged release oral dosage forms, with reliable performance profiles and robust and cost efficient production processes which can translate into improved patient safety and compliance."